Orrick, Herrington & Sutcliffe guides companies, investors and innovators through the full lifecycle of discovery, development, commercialisation and strategic growth. The firm's work spans pharma, biotech, medical devices, diagnostics, digital health and emerging biotech sectors. With a wide breadth of capabilities, the team provides an integrated litigation, IP, transactional and FDA offering to clients. In Washington, DC, global co-leader of the life sciences and healthtech sector Tony Chan focuses on representing private equity and strategic clients, while Thora Johnson is a trusted cyber, privacy and healthtech regulatory advisor. Fellow global co-chair Stephen Thau provides strategic advice to life sciences and tech companies from New York, while in Los Angeles David Gindler focuses on IP litigation and licensing.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Incredible depth of experience and if they don't have the experience they will find an expert quickly.’
‘Thoughtful, available, creative, trustworthy, experienced.’
‘Experienced attorneys with deep knowledge of corporate law and intellectual property protection.'
'The team we have worked with is responsive and willing to access whatever resources within the firm are necessary to provide the detailed guidance that we sometimes seek.'
'They are pleasant to work with and I view them as true colleagues and not mere service providers.’
Key clients
- Carlyle, SK Capital Partners and Beacon Parent Holdings
- Genentech
- Vanda Pharmaceuticals
- Regeneron Pharmaceuticals
- Johnson & Johnson
- Hinge Bio
- Bexorg
- DURECT Corporation
- Gilead Sciences, Inc.
- Ferring Pharmaceuticals
Work highlights
Advised Genentech in an international arbitration against Novartis resolving a high-stakes dispute over commercialization rights to ophthalmology blockbuster Vabysmo®.
Advised Vanda Pharmaceuticals on the exclusive license of imsidolimab from AnaptysBio to advance a late-stage therapy for Generalized Pustular Psoriasis.
Advised Carlyle, SK Capital Partners and Beacon Parent Holdings on the acquisition of bluebird bio (now Genetix Biotherapeutics), a biotechnology company developing potentially curative gene therapies.
Practice head
Tony Chan; Thora Johnson; Stephen Thau; David Gindler